To study retrospective, single-centre, observational assessing optimize post-marketing experience with ocrelizumab for multiple sclerosis (MS) at an academic medical center (UCSF) and describe the impact of a Unit-Based Leadership Team approach to identify and respond to procedural and safety-related concerns
Latest Information Update: 23 Jan 2020
Price :
$35 *
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 23 Jan 2020 New trial record